Can-Fite BioPharma (CANF) EPS (Basic) Growth (1y) (2017 - 2023)
Powered by 
Analysis
Can-Fite BioPharma (CANF) EPS (Basic) Growth (1y) (2017 - 2023) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Basic) Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 649.12 Bn | 628.36 Bn | 17.26 Bn | -0.10% |
| 2 | AbbVie | 445.86 Bn | 439.29 Bn | 12.70 Bn | 284.05% |
| 3 | Merck | 362.13 Bn | 354.99 Bn | 12.21 Bn | -130.68% |
| 4 | Novartis Ag | 268.88 Bn | 261.19 Bn | 11.24 Bn | -15.94% |
| 5 | Pfizer | 156.96 Bn | 145.26 Bn | 10.94 Bn | -108.11% |
| 6 | Sanofi | 52.26 Bn | 44.88 Bn | 10.79 Bn | -91.06% |
| 7 | Revolution Medicines | 42.98 Bn | 42.98 Bn | - | - |
| 8 | Incyte | 25.13 Bn | 20.59 Bn | 1.57 Bn | 39.99% |
| 9 | United Therapeutics | 21.56 Bn | 18.90 Bn | 683.80 Mn | 13.91% |
| 10 | Can-Fite BioPharma | 1.80 Mn | -1.19 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2023 | 0.99% |
| Sep 30, 2023 | 50.86% |
| Jun 30, 2023 | -28.95% |
| Mar 31, 2023 | 28.97% |
| Dec 31, 2022 | 80.10% |
| Sep 30, 2022 | 87.73% |
| Jun 30, 2022 | -77.43% |
| Mar 31, 2022 | 16.01% |
| Dec 31, 2021 | 26.53% |
| Sep 30, 2021 | 84.09% |
| Jun 30, 2021 | -88.06% |
| Dec 31, 2020 | 59.48% |
| Sep 30, 2020 | -414.51% |
| Jun 30, 2020 | 203.10% |
| Dec 31, 2019 | 90.20% |
| Sep 30, 2019 | 1,292.51% |
| Jun 30, 2019 | -209.76% |
| Mar 31, 2019 | 176.37% |
| Dec 31, 2018 | 13.48% |
| Sep 30, 2018 | -87.19% |